Tirzepatide: Dual GIP/GLP-1 Mechanism and the SURPASS and SURMOUNT Trial Programme

RESEARCH · TIRZEPATIDE

Tirzepatide: Dual GIP/GLP-1 Mechanism and the SURPASS and SURMOUNT Trial Programme

Tirzepatide is an acylated peptide engineered to activate two incretin receptors, GIP and GLP-1 [1]. It is among the most extensively studied peptides in metabolic medicine, which makes it a useful case study in how a mechanism, a clinical trial programme and a regulatory status fit together. This article summarises the published evidence and the limits of what it shows. Our earlier tirzepatide post covers shipping; this one is a literature overview. PurixLab’s Tirzepatide 10mg is a lyophilized research vial supplied for laboratory research use only.

The dual-agonist mechanism

The discovery paper describes LY3298176 (tirzepatide) as a fatty-acid-modified peptide designed for once-weekly administration. It activated both receptors in vitro, and in mice it produced glucose-dependent insulin secretion and, with chronic administration, decreased body weight and food intake to a significantly greater extent than a GLP-1 receptor agonist [2].

A later pharmacology study added nuance. Receptor-occupancy modelling indicated greater engagement of the GIP receptor than the GLP-1 receptor, and at the GLP-1 receptor tirzepatide showed bias toward cAMP generation over β-arrestin recruitment, with weaker receptor internalisation than native GLP-1. In primary islets, β-arrestin1 limited the insulin response to GLP-1 but not to GIP or tirzepatide [3]. A 2025 review argues that GIP-receptor activation in the brain, together with glucagon-receptor activity in liver and adipose tissue for triple agonists, may synergise with GLP-1 receptor agonism [4].

The clinical trial programme

  • SURPASS-1 (monotherapy in type 2 diabetes; 478 participants; 40 weeks). HbA1c fell by 1.87–2.07% across doses versus a 0.04% rise with placebo, with dose-dependent weight loss of 7.0–9.5 kg [5].
  • SURPASS-2 (versus semaglutide 1 mg; 1,879 patients; open-label; 40 weeks). HbA1c fell by 2.01–2.30 percentage points with tirzepatide versus 1.86 with semaglutide; all doses were noninferior and superior on the primary end point [6].
  • SURMOUNT-1 (obesity without diabetes; 2,539 adults; 72 weeks). Mean weight change was −15.0%, −19.5% and −20.9% across doses versus −3.1% with placebo; discontinuation for adverse events was 4.3–7.1% versus 2.6% [7].
  • SURMOUNT-5 (versus semaglutide; 751 adults; open-label; 72 weeks). Weight change was −20.2% with tirzepatide versus −13.7% with semaglutide [8].
  • SURMOUNT-OSA (obstructive sleep apnoea with obesity; two trials; 52 weeks). In trial 1 the apnoea–hypopnoea index changed by −25.3 events per hour versus −5.3 with placebo; in trial 2, −29.3 versus −5.5 [9].
  • SURPASS-CVOT (type 2 diabetes with atherosclerotic disease; 13,299 randomised; versus dulaglutide). The primary composite event occurred in 12.2% versus 13.1% (hazard ratio 0.92; 95.3% CI 0.83–1.01). Tirzepatide was noninferior (P = 0.003) but superiority was not shown (P = 0.09) [10].

A 2022 review of SURPASS 1–5 concluded that adverse events resembled those of selective GLP-1 agonists, mainly nausea, vomiting, diarrhoea and constipation, more common at higher doses [1].

What is still not known

  • Which receptor does what in humans. The 2022 review noted that while GIP reduces food intake and body weight in rodents, this had not been demonstrated in humans, and that it remained to be shown that GIP-receptor agonism improves insulin secretion in people with type 2 diabetes [1].
  • Open-label head-to-head design. SURPASS-2 and SURMOUNT-5 were open-label [6,8], and the trials cited here were funded by Eli Lilly [5,7,10].
  • Duration and outcomes. Treatment periods in the weight and glycaemic trials were 40–72 weeks. SURPASS-CVOT, the cardiovascular outcomes trial, showed noninferiority rather than superiority [10].

Approved drug products versus research-grade material

Health Canada issued a Notice of Compliance for Mounjaro (tirzepatide) on 24 November 2022, for glycaemic control in adults with type 2 diabetes [11], and the Health Canada NOC for Zepbound (chronic weight management) is dated 13 May 2025 [12]. Those are specific, sponsor-manufactured prescription products, assessed for quality, safety and efficacy. Health Canada’s advisory states that unauthorized tirzepatide products have not been assessed for safety, effectiveness or quality and warns against buying or using them [13]; separately, it states that “research use only” labelling does not make a product legal or exempt from regulatory requirements [14]. Every trial result above comes from tirzepatide studied in a regulated clinical-trial setting under medical supervision. It cannot be assumed to apply to any other material, including a research-grade lyophilized peptide used in vitro or in non-human models.

General laboratory storage background

Laboratories should always follow the product label, any batch documentation and their own approved procedures. As general background, peptide suppliers’ technical guides describe broadly similar practice for lyophilized (freeze-dried) peptides:

  • Keep it dry, dark and cold. Lyophilized peptides should be kept away from heat, light and moisture; for longer-term storage, guides commonly recommend about −20 °C [15,16].
  • Avoid condensation. Let a cold vial reach room temperature, ideally in a desiccator, before opening, then reseal promptly [16].
  • Limit freeze–thaw cycles. Aliquoting by planned experiment reduces freeze–thaw cycles and air exposure [15].
  • Solutions are short-lived. Peptides in solution have a much shorter shelf life than the dry powder [15,16].

This is general laboratory information, not a protocol, and it contains no instructions for human use.

Tirzepatide 10mg at PurixLab

Tirzepatide 10mg: a labelled lyophilized research vial with 10mg per vial, C$129 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tirzepatide-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Codes: WELCOME10 takes 10% off eligible orders below C$400; PURIX20 takes 20% off eligible orders of C$400 or more before discount and tax. One offer per order; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View Tirzepatide 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169. PubMed 36050763 · PMC9438179 · doi:10.1186/s12933-022-01604-7
  2. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PubMed 30473097 · PMC6308032 · doi:10.1016/j.molmet.2018.09.009
  3. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PubMed 32730231 · PMC7526454 · doi:10.1172/jci.insight.140532
  4. Samms RJ, Kusminski CM. A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity. Annu Rev Physiol. 2025;87(1):279-299. PubMed 39546586 · doi:10.1146/annurev-physiol-022724-105443
  5. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. PubMed 34186022 · doi:10.1016/S0140-6736(21)01324-6
  6. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PubMed 34170647 · doi:10.1056/NEJMoa2107519
  7. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PubMed 35658024 · doi:10.1056/NEJMoa2206038
  8. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. PubMed 40353578 · doi:10.1056/NEJMoa2416394
  9. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. PubMed 38912654 · PMC11598664 · doi:10.1056/NEJMoa2404881
  10. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409-2420. PubMed 41406444 · doi:10.1056/NEJMoa2505928
  11. Health Canada. Regulatory Decision Summary for Mounjaro (tirzepatide), Notice of Compliance 2022-11-24 (Drug and Health Products Portal). Health Canada RDS
  12. CDA-AMC (Canada's Drug Agency). Tirzepatide (Zepbound) draft reimbursement review report, 2026 (Health Canada NOC date May 13, 2025). CDA-AMC report
  13. Health Canada. Thinking about buying GLP-1 drugs like Ozempic or Mounjaro? Beware of fake or unauthorized products (public advisory, last updated 2026-01-21). Health Canada advisory
  14. Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm you (public advisory, 2026-04-09). Health Canada advisory
  15. GenScript. Peptide Storage and Handling Guidelines (technical resource). GenScript
  16. AAPPTec. Handling and Storage of Peptides — FAQ (technical resource). AAPPTec

Leave a Comment

Your email address will not be published. Required fields are marked *